<add><doc>
	<field name = "DATE">4-MAR-1987 17:07:06.01</field>
	<field name = "PLACES">usa</field>
	<field name = "UNKNOWN">F
f0878reute
r f BC-HUNTERDON-HUNT>-SETS   03-04 0105</field>
	<field name = "TITLE">HUNTERDON HUNT> SETS DENTAL VENTURE</field>
	<field name = "DATELINE">YARDLEY, Penn., March 4 -</field>
	<field name = "BODY">Hunterdon Pharmaceuticals Inc
said it formed a joint venture with Chesapeake Biological
Laboratories> and E.B. Michaels Research Associates> to
develop C31G, a substance that may be useful in the treatment
or prevention of plaque.
    The substance, tested in pre-clinical trials at the
University of Pennsylvania, also has other uses as an
anti-fungal or anti-bacterial agent, the company said.
    It said Chesapeake Biological, a private company, owns 55
pct of the venture, E.B. Michaels 10 pct, while it holds the
remaining interest, and the patent for C31G.
 Reuter</field>
</doc></add>
